Efficacy of aerosol inhalation of tiotropium and symbicort on FeNO, total IgE in serum, inflammatory factors and lung function in patients with asthma-chronic obstructive pulmonary disease overlap syndrome
{"title":"Efficacy of aerosol inhalation of tiotropium and symbicort on FeNO, total IgE in serum, inflammatory factors and lung function in patients with asthma-chronic obstructive pulmonary disease overlap syndrome","authors":"Xu Feng, Hongjie Guo","doi":"10.3760/CMA.J.ISSN.1674-4756.2020.03.026","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the efficacy of aerosol inhalation of tiotropium and symbicort on FeNO, total IgE in serum, inflammatory factors and lung function in patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS). \n \n \nMethods \nThe clinical data of 124 ACOS patients admitted to the First Affiliated Hospital of Nanyang Medical College from January 2017 to March 2019 were retrospectively analyzed. According to the treatment methods, the patients were divided into observation group and control group, with 62 cases in each group. Patients in control group was given symbicort inhalation therapy on the basis of conventional symptomatic treatment, and patients in observation group was given tiotropium inhalation therapy on the basis of treatment of control group. All patients were continuously treated for 12 weeks. The (FeNO), serum total IgE, airway-related inflammatory factors, such as leukotriene B4 (LTB4), interleukin-6 (IL-6), myeloperoxidase (MPO), 8-isoprostanes (8-isoPG), lung function indicators, such as forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC value and symptoms scores, such as Asthma Control Test (ACT), chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) were compared between the two groups, and the occurrence of adverse effects was monitored. \n \n \nResults \nAfter treatment, the levels of FeNO and serum total IgE in the two groups were significantly lower than those before treatment (P 0.05. \n \n \nConclusions \nCompared with symbicort inhalation therap, tiotropium combined with symbicort inhalation therapy for patients with ACOS can improve the allergic reactions, airway inflammatory response, lung function and symptoms without increasing incidence of adverse effects. \n \n \nKey words: \nAsthma-chronic obstructive pulmonary disease overlap syndrome; Tiotropium; Glucocorticoid; Fractional exhaled nitric oxide; Serum total immunoglobin E; Lung function","PeriodicalId":9667,"journal":{"name":"Central Plains Medical Journal","volume":"23 1","pages":"97-101"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central Plains Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1674-4756.2020.03.026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To observe the efficacy of aerosol inhalation of tiotropium and symbicort on FeNO, total IgE in serum, inflammatory factors and lung function in patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS).
Methods
The clinical data of 124 ACOS patients admitted to the First Affiliated Hospital of Nanyang Medical College from January 2017 to March 2019 were retrospectively analyzed. According to the treatment methods, the patients were divided into observation group and control group, with 62 cases in each group. Patients in control group was given symbicort inhalation therapy on the basis of conventional symptomatic treatment, and patients in observation group was given tiotropium inhalation therapy on the basis of treatment of control group. All patients were continuously treated for 12 weeks. The (FeNO), serum total IgE, airway-related inflammatory factors, such as leukotriene B4 (LTB4), interleukin-6 (IL-6), myeloperoxidase (MPO), 8-isoprostanes (8-isoPG), lung function indicators, such as forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC value and symptoms scores, such as Asthma Control Test (ACT), chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) were compared between the two groups, and the occurrence of adverse effects was monitored.
Results
After treatment, the levels of FeNO and serum total IgE in the two groups were significantly lower than those before treatment (P 0.05.
Conclusions
Compared with symbicort inhalation therap, tiotropium combined with symbicort inhalation therapy for patients with ACOS can improve the allergic reactions, airway inflammatory response, lung function and symptoms without increasing incidence of adverse effects.
Key words:
Asthma-chronic obstructive pulmonary disease overlap syndrome; Tiotropium; Glucocorticoid; Fractional exhaled nitric oxide; Serum total immunoglobin E; Lung function